An educational programme for General Practice developed by international experts – Dr Lawrence Leiter and Dr Subodh Verma (Canada)

WHAT WILL YOU GAIN…

Participation in this fully accredited CPD programme gives you the opportunity to learn how:

• To interpret latest data on cardiovascular protection
• Differentiate cardiovascular outcome trial results practically to identify at-risk patients in your practice
• The benefits and risks of SGLT-2 inhibitor therapy
• To understand the renal benefits of SGLT-2 inhibitors and apply this therapy in your practice

WHAT WILL YOU LEARN…

Dr Lawrence A Leiter Division of Endocrinology and Metabolism St Michael’s Hospital Professor of Medicine and Nutritional Sciences, University of Toronto, Toronto, ON, Canada.		Dr Subodh Verma Division of Cardiac Surgery St Michael’s Hospital Professor of Surgery and Pharmacology & Toxicology University of Toronto, Toronto, ON, Canada Canada Research Chair in Cardiovascular Surgery

OUR LEARNING MODULES
 
EARN 15 CPD points by completing this programme

ACT 1: Cardiovascular and renal protection in diabetes »
ACT 2: Cardiovascular outcome trials in diabetes »
ACT 3: Renal protection in diabetes »
ACT 4: Review of renal therapies prior to SGLT-2 inhibitor therapy »
ACT 5: Renal benefits of SGLT-2 inhibitors in diabetes »
ACT 6: SGLT-2 inhibitors and safety »

Each module provides knowledge and expert comment

Supported by an unrestricted grant